Englander Institute for Precision Medicine

Publications

Found 692 results
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Bovonratwet P, Kulm S, Kolin DA, Song J, Morse KW, Cunningham ME, Albert TJ, Sandhu HS, Kim HJo, Iyer S et al..  2023.  Identification of Novel Genetic Markers for the Risk of Spinal Pathologies: A Genome-Wide Association Study of 2 Biobanks.. J Bone Joint Surg Am.
Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D et al..  2018.  SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.. Clin Cancer Res. 24(22):5585-5593.
Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.
Brendel M, Su C, Bai Z, Zhang H, Elemento O, Wang F.  2022.  Application of Deep Learning on Single-cell RNA Sequencing Data Analysis: A Review.. Genomics Proteomics Bioinformatics. 20(5):814-835.
Brendel M, Getseva V, Assaad MAl, Sigouros M, Sigaras A, Kane T, Khosravi P, Mosquera JMiguel, Elemento O, Hajirasouliha I.  2022.  Weakly-supervised tumor purity prediction from frozen H&E stained slides.. EBioMedicine. 80:104067.
Brown JA, Sanidad KZ, Lucotti S, Lieber CM, Cox RM, Ananthanarayanan A, Basu S, Chen J, Shan M, Amir M et al..  2022.  Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection.. Gut Microbes. 14(1):2105609.
Bruno NE, Nwachukwu JC, Srinivasan S, Nettles CC, Izard T, Jin Z, Nowak J, Cameron MD, Boregowda SV, Phinney DG et al..  2021.  Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.. Nat Chem Biol. 17(3):307-316.
Buqué A, Perez-Lanzón M, Petroni G, Humeau J, Bloy N, Yamazaki T, Sato A, Kroemer G, Galluzzi L.  2021.  MPA/DMBA-driven mammary carcinomas.. Methods Cell Biol. 163:1-19.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):4787.
Buqué A, Bloy N, Kroemer G, Galluzzi L.  2021.  Possible mechanisms of cancer prevention by nicotinamide.. Br J Pharmacol. 178(10):2034-2040.
Buqué A, Bloy N, Petroni G, Kroemer G, Galluzzi L.  2020.  NK cells beat T cells at early breast cancer control.. Oncoimmunology. 9(1):1806010.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.
Buqué A, Galluzzi L, Montrose DC.  2021.  Targeting Serine in Cancer: Is Two Better Than One? Trends Cancer. 7(8):668-670.
Buqué A, Galluzzi L, Kroemer G.  2021.  Ketosis versus carbotoxicity - metabolism determines the outcome of cancer immunotherapy.. Mol Cell Oncol. 8(1):1868266.
Butler DJ, Mozsary C, Meydan C, Danko D, Foox J, Rosiene J, Shaiber A, Afshinnekoo E, MacKay M, Sedlazeck FJ et al..  2020.  Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions.. bioRxiv.
Butler D, Mozsary C, Meydan C, Foox J, Rosiene J, Shaiber A, Danko D, Afshinnekoo E, MacKay M, Sedlazeck FJ et al..  2021.  Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions.. Nat Commun. 12(1):1660.
Buyukozkan M, Alvarez-Mulett S, Racanelli AC, Schmidt F, Batra R, Hoffman KL, Sarwath H, Engelke R, Gomez-Escobar L, Simmons W et al..  2022.  Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19.. iScience. 25(7):104612.
Buyukozkan M, Suhre K, Krumsiek J.  2022.  SGI: automatic clinical subgroup identification in omics datasets.. Bioinformatics. 38(2):573-576.
C
Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, Gaffney CD, Shoag J, Tu JJenny, Khani F et al..  2022.  A multidisciplinary approach to optimize primary prostate cancer biobanking.. Urol Oncol. 40(6):271.e1-271.e7.
Cai L, Tsai Y-H, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM et al..  2018.  ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.. Mol Cell. 72(2):341-354.e6.
M Calvo-Vidal N, Zamponi N, Krumsiek J, Stockslager MA, Revuelta MV, Phillip JM, Marullo R, Tikhonova E, Kotlov N, Patel J et al..  2021.  Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.. Cancer Res. 81(20):5202-5216.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.. Cell Rep. 34(5):108707.
Casiraghi N, Orlando F, Ciani Y, Xiang J, Sboner A, Elemento O, Attard G, Beltran H, Demichelis F, Romanel A.  2020.  ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA.. Bioinformatics. 36(9):2665-2674.
Catanzaro E, Demuynck R, Naessens F, Galluzzi L, Krysko DV.  2024.  Immunogenicity of ferroptosis in cancer: a matter of context? Trends Cancer.